[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA44637A1 - Composes hétérocycliques et leurs utilisations - Google Patents

Composes hétérocycliques et leurs utilisations

Info

Publication number
MA44637A1
MA44637A1 MA44637A MA44637A MA44637A1 MA 44637 A1 MA44637 A1 MA 44637A1 MA 44637 A MA44637 A MA 44637A MA 44637 A MA44637 A MA 44637A MA 44637 A1 MA44637 A1 MA 44637A1
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
preparation
methods
relates
present
Prior art date
Application number
MA44637A
Other languages
English (en)
Other versions
MA44637B1 (fr
Inventor
Mingda Bi
Robert Kuehl
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of MA44637A1 publication Critical patent/MA44637A1/fr
Publication of MA44637B1 publication Critical patent/MA44637B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne certaines formulations pharmaceutiques d'omécamtiv mécarbil et leurs procédés de préparation et d'utilisation.
MA44637A 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations MA44637B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (fr) 2013-03-14 2014-03-14 Composés hétérocycliques et leurs utilisations

Publications (2)

Publication Number Publication Date
MA44637A1 true MA44637A1 (fr) 2019-08-30
MA44637B1 MA44637B1 (fr) 2021-04-30

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38399A MA38399B2 (fr) 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MA44637A MA44637B1 (fr) 2013-03-14 2014-03-14 Composes hétérocycliques et leurs utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38399A MA38399B2 (fr) 2013-03-14 2014-03-14 Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique

Country Status (41)

Country Link
US (14) US9988354B2 (fr)
EP (3) EP3821882A1 (fr)
JP (5) JP6498658B2 (fr)
KR (2) KR102374159B1 (fr)
CN (3) CN105209437B (fr)
AP (1) AP2015008789A0 (fr)
AR (2) AR095542A1 (fr)
AU (2) AU2014240049C1 (fr)
BR (2) BR112015022857B1 (fr)
CA (3) CA3147180C (fr)
CL (1) CL2015002708A1 (fr)
CR (1) CR20150549A (fr)
CY (2) CY1122695T1 (fr)
DK (2) DK2970123T3 (fr)
EA (1) EA031185B1 (fr)
ES (2) ES2750676T3 (fr)
HK (4) HK1218080A1 (fr)
HR (2) HRP20191728T1 (fr)
HU (2) HUE052355T2 (fr)
IL (2) IL240788B (fr)
JO (1) JOP20140114B1 (fr)
LT (2) LT2968173T (fr)
MA (2) MA38399B2 (fr)
ME (1) ME03566B (fr)
MX (3) MX363347B (fr)
MY (1) MY186048A (fr)
NZ (1) NZ711225A (fr)
PE (1) PE20151786A1 (fr)
PH (2) PH12015501998B1 (fr)
PL (2) PL2970123T3 (fr)
PT (2) PT2970123T (fr)
RS (2) RS61215B1 (fr)
RU (1) RU2663663C2 (fr)
SA (1) SA515361088B1 (fr)
SG (2) SG11201507258PA (fr)
SI (2) SI2968173T1 (fr)
TN (1) TN2015000380A1 (fr)
TW (1) TWI667026B (fr)
UA (1) UA117011C2 (fr)
UY (1) UY35449A (fr)
WO (2) WO2014152236A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095542A1 (es) * 2013-03-14 2015-10-21 Amgen Inc Compuestos heterocíclicos y sus usos
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
EP3313444B1 (fr) 2015-06-26 2020-10-21 Amgen Inc. Traitement combiné comprenant un activateur de la myosine cardiaque et un inhibiteur des canaux if du noeud sinusal
TWI847144B (zh) * 2017-06-30 2024-07-01 美商安進公司 奧美卡替莫卡必爾的合成
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
US11608318B2 (en) * 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) * 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
US20220185791A1 (en) * 2019-03-12 2022-06-16 Amgen Inc. Polymorphs of a cardiac troponin activator
EP3938041A1 (fr) * 2019-03-12 2022-01-19 Amgen Inc. Polymorphes et co-cristaux d'un activateur de troponine cardiaque
EP4045492A1 (fr) 2019-09-19 2022-08-24 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
WO2021053189A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
WO2021070123A1 (fr) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
IL295490A (en) * 2020-02-10 2022-10-01 Amgen Inc omecamtiv mecarbil tablet
US20220184068A1 (en) 2020-11-12 2022-06-16 Cytokinetics, Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
BR112023018095A2 (pt) 2021-03-10 2023-12-12 Amgen Inc Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo
WO2024081611A1 (fr) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) * 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
CZ20022046A3 (cs) 1999-12-23 2002-11-13 Pfizer Products Inc. Hydrogelem hnaná dávková forma účinné sloľky
GB0124455D0 (en) 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
WO2003032965A2 (fr) 2001-10-17 2003-04-24 King Pharmaceuticals Research And Development, Inc Methode de reduction du diabete de type 2 chez des patients a haut risque
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
PT1765327E (pt) * 2004-06-17 2014-11-24 Cytokinetics Inc Compostos, composições e métodos
WO2007054975A1 (fr) 2005-11-08 2007-05-18 Panacea Biotec Ltd Compositions pharmaceutiques destinees au traitement de troubles cardiovasculaires et d'autres troubles associes
PE20100742A1 (es) 2005-11-15 2010-11-25 Glaxo Group Ltd Nuevos procedimientos y formulaciones
WO2007070683A2 (fr) * 2005-12-15 2007-06-21 Cytokinetics, Inc. Entites chimiques, compositions et procedes
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078839A2 (fr) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Composes, compositions et methodes
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
JP5591245B2 (ja) 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
AR095542A1 (es) * 2013-03-14 2015-10-21 Amgen Inc Compuestos heterocíclicos y sus usos
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
WO2016123291A1 (fr) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
EP3313444B1 (fr) 2015-06-26 2020-10-21 Amgen Inc. Traitement combiné comprenant un activateur de la myosine cardiaque et un inhibiteur des canaux if du noeud sinusal
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
TWI847144B (zh) 2017-06-30 2024-07-01 美商安進公司 奧美卡替莫卡必爾的合成
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (fr) 2018-12-18 2020-06-25 Amgen Inc. Procédé de réduction de composés nitro aromatiques
EP4045492A1 (fr) 2019-09-19 2022-08-24 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
WO2021053189A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
WO2021070123A1 (fr) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
IL295490A (en) 2020-02-10 2022-10-01 Amgen Inc omecamtiv mecarbil tablet
US20220184068A1 (en) 2020-11-12 2022-06-16 Cytokinetics, Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (fr) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Forme cristalline non hydratée de sel de dihydrobromure d'omecamtiv mecarbil
BR112023018095A2 (pt) 2021-03-10 2023-12-12 Amgen Inc Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo

Also Published As

Publication number Publication date
EP3821882A1 (fr) 2021-05-19
NZ750950A (en) 2020-09-25
IL240788A0 (en) 2015-10-29
US10421726B2 (en) 2019-09-24
BR112015022857A2 (pt) 2017-07-18
US20240317687A1 (en) 2024-09-26
SA515361088B1 (ar) 2018-07-22
RU2663663C2 (ru) 2018-08-08
JP6966590B2 (ja) 2021-11-17
PL2970123T3 (pl) 2020-03-31
BR112015023417B1 (pt) 2023-10-17
RS61215B1 (sr) 2021-01-29
KR102374159B1 (ko) 2022-03-15
EP2970123B1 (fr) 2019-08-14
HUE052355T2 (hu) 2021-04-28
MA38399A1 (fr) 2017-01-31
IL240788B (en) 2020-09-30
PT2970123T (pt) 2019-10-28
KR20150136063A (ko) 2015-12-04
CN108785265A (zh) 2018-11-13
AU2014240049B2 (en) 2018-07-19
US11472773B2 (en) 2022-10-18
JP2016519071A (ja) 2016-06-30
IL241089A0 (en) 2015-11-30
PH12019500176A1 (en) 2020-11-04
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
BR112015023417A2 (pt) 2017-07-18
CR20150549A (es) 2016-01-04
US20220298114A1 (en) 2022-09-22
CA2902436A1 (fr) 2014-09-25
CA3147180C (fr) 2024-04-23
EA201591728A1 (ru) 2016-01-29
CA2902646C (fr) 2022-08-16
US20180273479A1 (en) 2018-09-27
EP2968173A1 (fr) 2016-01-20
MY186048A (en) 2021-06-17
LT2970123T (lt) 2019-11-11
ES2837038T3 (es) 2021-06-29
MX2021001231A (es) 2021-04-12
PE20151786A1 (es) 2015-12-11
UY35449A (es) 2014-09-30
CY1122695T1 (el) 2021-03-12
CA2902646A1 (fr) 2014-09-25
HUE046285T2 (hu) 2020-02-28
ME03566B (fr) 2020-07-20
MX2015012429A (es) 2016-04-07
SI2970123T1 (sl) 2019-12-31
US20200331859A1 (en) 2020-10-22
AU2014239995A1 (en) 2015-09-10
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
CN108785265B (zh) 2024-10-08
HK1218544A1 (zh) 2017-02-24
JP6498658B2 (ja) 2019-04-10
JP7174132B2 (ja) 2022-11-17
US20160016906A1 (en) 2016-01-21
SI2968173T1 (sl) 2021-04-30
PL2968173T3 (pl) 2021-03-08
JOP20140114B1 (ar) 2021-08-17
IL241089B (en) 2019-10-31
MX2015012414A (es) 2016-04-25
WO2014152270A1 (fr) 2014-09-25
AU2014240049A1 (en) 2015-09-10
RU2015143643A (ru) 2017-04-18
JP6689942B2 (ja) 2020-04-28
CL2015002708A1 (es) 2016-03-11
PH12015501998A1 (en) 2016-01-11
CN105209437A (zh) 2015-12-30
US20200399221A1 (en) 2020-12-24
JP2019059746A (ja) 2019-04-18
UA117011C2 (uk) 2018-06-11
US20140309235A1 (en) 2014-10-16
AU2014239995B2 (en) 2018-07-26
EP2968173B1 (fr) 2020-10-14
TWI667026B (zh) 2019-08-01
HK1219484A1 (zh) 2017-04-07
KR20220045014A (ko) 2022-04-12
US9988354B2 (en) 2018-06-05
ES2750676T3 (es) 2020-03-26
NZ711225A (en) 2020-06-26
US20200277261A1 (en) 2020-09-03
JP2020125307A (ja) 2020-08-20
SG10201706656RA (en) 2017-09-28
US20240101517A1 (en) 2024-03-28
US11884630B2 (en) 2024-01-30
AR129504A2 (es) 2024-09-04
WO2014152236A1 (fr) 2014-09-25
HK1218080A1 (zh) 2017-02-03
DK2968173T3 (da) 2020-12-21
EA031185B1 (ru) 2018-11-30
JP2016513683A (ja) 2016-05-16
JP2022023891A (ja) 2022-02-08
TW201524507A (zh) 2015-07-01
AP2015008789A0 (en) 2015-10-31
CN105120844A (zh) 2015-12-02
HRP20191728T1 (hr) 2019-12-13
AR095542A1 (es) 2015-10-21
CY1123633T1 (el) 2022-03-24
HK1218512A1 (zh) 2017-02-24
KR102474467B1 (ko) 2022-12-05
TN2015000380A1 (en) 2017-01-03
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
US20220153700A1 (en) 2022-05-19
CN105209437B (zh) 2018-09-18
HRP20201967T1 (hr) 2021-03-05
LT2968173T (lt) 2021-03-25
MA38399B2 (fr) 2020-12-31
US20230044617A1 (en) 2023-02-09
SG11201507258PA (en) 2015-10-29
DK2970123T3 (da) 2019-10-21
PH12015501998B1 (en) 2016-01-11
EP2970123A1 (fr) 2016-01-20
RS59536B1 (sr) 2019-12-31
US11384053B2 (en) 2022-07-12
PT2968173T (pt) 2020-12-18
US20200079736A1 (en) 2020-03-12
BR112015022857B1 (pt) 2022-10-25
AU2014240049C1 (en) 2019-03-07
CA3147180A1 (fr) 2014-09-25

Similar Documents

Publication Publication Date Title
MA44637A1 (fr) Composes hétérocycliques et leurs utilisations
MA53356A (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MX2015017964A (es) Inhibidores de bromodominio.
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
MX2015012416A (es) Compuestos heterociclicos y sus usos.
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
TR201010859A2 (tr) Sefdinir içeren tablet formları.
FR3010999B1 (fr) Glycoclusters et leurs utilisations pharmaceutiques en tant qu'antibacteriens
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
MA35947B1 (fr) Anticorps et immunoconjugués anti-lgr5
MA38426B1 (fr) Compositions antibiotiques de ceftolozane
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.
MA38492A1 (fr) Anticorps et immunoconjugués anti-b7-h4